Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11324889 | 1.00 | MBTPS1 (0.67) | MBTPS1SMN1; SMN2ALDH1A1KDM4ENPSR1 | |
| SCHEMBL10354569 | 0.87 | SDCBP (0.59) | MBTPS1SMN1; SMN2ALDH1A1KDM4ENPSR1 | |
| SCHEMBL17996008 | 0.87 | CYP2C9 (0.57) | MBTPS1SMN1; SMN2ALDH1A1KDM4ENPC1 | |
| SCHEMBL4734519 | 0.86 | RECQL (0.67) | MBTPS1SMN1; SMN2NPSR1RAB9AKMT2A | |
| SCHEMBL9633343 | 0.86 | SMN1; SMN2 (0.53) | MBTPS1SMN1; SMN2ALDH1A1KDM4ENPSR1 | |
| SCHEMBL8548807 | 0.85 | GPR132 (0.55) | MBTPS1SMN1; SMN2ALDH1A1KDM4ERAB9A | |
| SCHEMBL8548803 | 0.85 | GPR132 (0.55) | MBTPS1SMN1; SMN2ALDH1A1KDM4ERAB9A | |
| SCHEMBL11323476 | 0.84 | ALDH1A1 (0.75) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL25556937 | 0.84 | SMN1; SMN2 (0.83) | SMN1; SMN2ALDH1A1KDM4ENPSR1NPC1 | |
| SCHEMBL11323461 | 0.84 | ALDH1A1 (0.75) | SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839665-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2017-12-12 | — | — | US | disclosed |
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-9345742-B2 | Aminostatin derivatives for the treatment of arthrosis | MERCK PATENT GMBH (DE) | 2016-05-24 | — | — | US | disclosed |
| EP-1103560-B1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-12-27 | — | — | EP | disclosed |
| US-6410576-B1 | ANTIINFLAMMATORY AGENTS; CARDIOVASCULAR DISORDERS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1103560-A1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
| US-4252952-A | 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-02-24 | — | — | US | disclosed |
| US-4178445-A | 7-(α-Substituted glycinamido)-3-substituted methyl-3-cephem-4-carboxylic acids and their derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1979-12-11 | — | — | US | disclosed |
| US-4039536-A | 7-(α-SUBSTITUTED GLYCINAMIDO)-3-SUBSTITUTED METHYL-3-CEPHEM-4-CARBOXYLIC ACIDS AND THEIR DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228493-A1 | AMINOSTATIN DERIVATIVES FOR THE TREATMENT OF ARTHROSIS | CTSD, CTSB, CTSZ | MBTPS1 2816/4885SMN1; SMN2 3956/4885ALDH1A1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.